

EQUITY RESEARCH



KIMS HOSPITAL LIMITED



FIN2RESEARCH
Investment Advisor Pvt. Ltd.



Rating

Business ★ ★ ★ ★ ★

Financials ★ ★ ★ ★ ★

Valuation ★ ★ ★ ★ ★

Management ★ ★ ★ ★ ★

Company : Krishna Institute of Medical Sciences Ltd . Sector : Hospital.


Buy Range : ₹ 660-680 Target- 1 : ₹740 Target- 2 : ₹830 Potential Upside: 23.00% Research Report

Stock Info	
Market Cap (₹ in cr)	26906.00
52-Weeks High/Low	708.00/350.00
Avg Volume	7,04,002
No. of eq shares (cr)	40.00
Face Value	2.00
Bse Code	543308
Nse Code	KIMS
Free Float (cr)	16463.70

Source : NSE/BSE		
Particulars	2024	2025
Bed Capacity	3975	5179
Operational Beds	3503	4492
Occupancy	61.30%	50.10%
ARPOB(Rs.)	31916	39158
ARPP(Rs.)	131232	143293
ROCE (%)	16.54%	14.73%
ROE (%)	16.67%	18.39%
ROA (%)	10.00%	8.72%
Equity/Assets	0.54	0.42

Source : Company		
Particulars	2024	2025
Promoters	38.82%	38.82%
Mutual Funds/AIF	26.33%	25.35%
Insurance co.	5.61%	6.20%
Other DIIs	1.19%	0.40%
FII	16.73%	15.45%
Retails and Others	11.32%	13.78%
Total	100.00%	100.00%

Source : NSE/BSE	
Particulars	TTM
P/E	66.56
P/B	12.86
EV/EBITDA	35.98
P/S	8.86
EPS	9.61
P/CF	46.25



KIMS Hospital Limited: Krishna Institute of Medical Sciences Ltd (KIMS), headquartered in Secunderabad, Telangana, is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana in terms of the number of patients treated and the range of treatments provided. Incorporated in 1973, KIMS offers a comprehensive range of multidisciplinary healthcare services, including primary, secondary, and tertiary care across tier-2 and tier-3 cities, along with a quaternary care facility in tier-1 cities. Its medical offerings span various specialties such as oncology, cardiac sciences, neurosciences, gastric sciences, orthopedics, renal sciences, organ transplantation, and mother and child care, among others.

Key Highlights:

- In FY25, the company saw strong operational performance with average revenue per operating bed rising 22.7% YoY and average revenue per patient up 9.2% YoY. Inpatient (IP) and outpatient (OP) volumes grew 11.6% and 14.1%, respectively. The year also saw significant expansion and upgrades, including the launch of two new units in Guntur (Andhra Pradesh) and Sangli (Maharashtra), expected to contribute ₹10 crore in FY26..
- As of March 31, 2025, KIMS operates 101 units across Telangana, Andhra Pradesh, Maharashtra, Kerala (with upcoming facilities in Karnataka), totaling 5,179 beds, of which 4,492 are operational. Telangana hosts several major campuses, including a 1,000-bed facility in Secunderabad and a 290-bed hospital in Begumpet, alongside newer units in Kondapur and Gachibowli. Andhra Pradesh features multiple hospitals, such as a 434-bed center in Vizag and growing capacities in Srikakulam, Rajahmundry, Ongole, Kurnool, Nellore, Anantapur, and Guntur. In Maharashtra, KIMS expanded into Nagpur, Nashik, Thane, and Sangli, while Kerala's Kannur and Kollam units have begun operations. Upcoming expansions in Bengaluru will add 800 beds across two new hospitals.
- Cluster-level performance in Q4 FY 25 varies by region. In Telangana, bed capacity grew slightly to 1,797, with operational beds at 1,682. The cluster achieved 22,322 IP cases and 221,049 OP cases, with ARPOB rising to INR 65,375 and occupancy at 50.6%, driving EBITDA margins to 32.3%. Andhra Pradesh expanded capacity to 2,214 beds but saw occupancy fall to 54.6% as IP cases rose to 23,929 and OP cases to 174,765; ARPOB jumped to INR 23,668 and ARPP to INR 87,721. Maharashtra's two operational units grew capacity to 659 beds, though occupancy averaged 36.6% in Q4, with ARPOB at INR 32,591. Kerala's Kannur and Kollam facilities, totaling 189 beds, achieved 47.4% occupancy, and ARPOB improved to INR 32,727 despite lower IP volumes.
- In FY25, the company expanded its footprint by opening hospitals in Nashik and Sangli (Maharashtra), Kannur and Kollam (Kerala), and Guntur (Andhra Pradesh). In April FY25, a second unit in Vizag—KIMS Seethammadhara—was launched, along with a fertility center, pediatric and childcare unit under the "Cuddles" brand, and a specialty center in Vizag. Additionally, two hospitals in Bangalore are set to open in the current year, now in the final stages of completion. These expansions significantly enhance the company's reach and growth potential.
- In Q4 FY25, KIMS' Telangana cluster saw a ~200 bps QoQ EBITDA margin expansion, driven by a stronger specialty mix and revenue growth, despite stable occupancy and losses from new units. Key contributors included the addition of a liver transplant team in Secunderabad and specialist onboarding at the upcoming Kondapur facility. With further capacity at Sunshine and new units in the pipeline, the cluster is expected to sustain or improve margins, with 32% likely becoming the new norm.
- KIMS is pursuing aggressive brownfield and greenfield expansion across Tier 1 cities (Bangalore, Mumbai/Thane, Hyderabad) and Tier 2/3 markets (Andhra, Kerala), following a cluster-based strategy to account for regional dynamics. Its "Cuddles" mother & child brand operates at 8 locations, contributing ~10% of revenue, with further growth planned. The group has established mature transplant programs in Telangana and is expanding oncology services to more centers. Additionally, 800–1,000 beds are expected to be added under the O&M model by FY27, offering high-margin income without impacting reported bed or occupancy metrics.

Key Risk :

- KIMS faces the general risks of Indian hospitals. Regulatory clampdowns on pricing could compress margins and returns. Execution risk is significant: the near-term plan involves heavy capex and ~1,000–1,700 new beds in the next 1–2 years. If patient volumes do not ramp as expected (occupancy may take time to improve beyond ~50%), start-up losses could widen and pressure cash flows
- The risks include dependence on Andhra/Telangana economies, medical manpower shortages, and any reversals in elective care (e.g. pandemic waves, policy changes in insurance reimbursements).

RATING SCALE: DEFINITION OF RATINGS

- **BUY** – We expect the stock to deliver more than 10%-20% returns over the next 9 months.
- **ACCUMULATE** – We expect the stock to deliver 5% - 12% returns over the next 9 months.
- **REDUCE** – We expect the stock to deliver 0% - 5% returns over the next 9 months.
- **SELL** – We expect the stock to deliver negative returns over the next 9 months.
- **NR** – Not Rated. Fin2Research is not assigning any rating or price target to the stock. The report has been prepared for information purposes only.
- **RS** – Rating Suspended. Fin2Research has suspended the investment rating and price target for this stock, either because there is not a Sufficient fundamental basis for determining, or there are legal, regulatory or policy constraints around publishing, an investment rating or target. The previous investment rating and price target, if any, are no longer in effect for this stock and should not be relied upon.
- **NA** – Not Available or Not Applicable. The information is not available for display or is not applicable.
- **NM** – Not Meaningful. The information is not meaningful and is therefore excluded.
- **NOTE** – Our target prices are with a 9-month perspective. Returns stated in the rating scale are our internal benchmark.

DISCLAIMER

ANALYST CERTIFICATION

I Ashish Sanwariya Research Analyst, author, and the name subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my views about the subject issuer(s) or securities. I also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above-mentioned Analyst of this report has not received any compensation from the companies mentioned in the report in the preceding twelve months and does not serve as an officer, director, or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by Sebi and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum, or risk-free return to the investors.

Fin2research Investment Advisor Private Limited (FIA) is the source of information and opinions in this report, which may be subject to change at any time. Any and all content in this report is confidentially sourced only for that intended audience and may not be altered, transmitted (in whole or in part), copied into another medium, or reproduced elsewhere without the written permission of Fin2research Investment Advisor Private Limited (FIA). Although we will endeavor to update the information contained herein for reasonable reasons, Fin2research Investment Advisor Private Limited (FIA) has no obligation to update or keep this information current. Due to regulatory, compliance, or other reasons, Fin2research Investment Advisor Private Limited (FIA) may be unable to do so.

The accuracy of this report is not guaranteed and it relies on information from public sources that have not been independently verified. This report and the information contained in it are for informational purposes only and should not be used or considered as an offer document or as an invitation to buy, sell, or subscribe to securities or other financial instruments. Although it is distributed to all clients at the same time, not all clients can receive this report at the same time. Fin2research Investment Advisor Private Limited (FIA) will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting, or tax advice or a representation that any investment or strategy is or would be appropriate for your particular circumstances.

The securities mentioned and opinions expressed in this document might not be appropriate for all investors, who have to make their very own investment decisions, primarily based totally on their very own investment objectives, economic positions, and needs of the particular recipient. This may not be taken in substitution for the exercising of independent judgment through any recipient. The recipient must independently compare the investment risks. Any number of factors, including fluctuations in interest rates and foreign exchange rates, could affect the value and return on investment. Fin2research Investment Advisor Private Limited (FIA) disclaims all responsibility for any form of loss or damage resulting from using this material. Future performance is not always predicted by past performance. Before making an investment in the securities markets, investors are recommended to review the Risk Disclosure Document to understand the risks involved. Actual results may differ materially from those set forth in projections. Statements that are deemed forward-looking are not guarantees and could change at any time.

As of the final day of the month before the research report was published, none of the following parties owned 1% or more of the equity securities of the company mentioned in the study: Fin2research Investment Advisor Private Limited (FIA), all of its subsidiaries, research analysts, or any family members of any of these parties.

The material contained in this study may not align with previous reports published by Fin2research Investment Advisor Private Limited (FIA) or reach a different conclusion. Fin2research Investment Advisor Private Limited (FIA) and its Research Analysts have not participated in any market-making activities on behalf of the firms listed in the report. We contend that no regulatory authority has taken any significant disciplinary action against Fin2research Investment Advisor Private Limited (FIA) that would have an impact on the company's ability to conduct equity research analysis.

The distribution, publication, availability, or use of this report by any person or entity that is a citizen or resident of, or located in, any locality, state, country, or other jurisdiction is not authorized or intended, as it may violate legal requirements or subject Fin2research Investment Advisor Private Limited (FIA) and affiliates to registration or licensing requirements in such jurisdictions. Certain groups of investors or all jurisdictions may not be able to purchase the securities covered here. It is expected of everyone who may come into possession of this material to become aware of and abide by these restrictions.

THANK YOU

Fin2Research Investment Advisor Pvt Ltd (FIA)

CIN: U70200DL2023PTC413207IA

Registration No: INA000018425

Registered Office: Plot No A 2nd Floor, Street New Bungalow Road, Malka Ganj, Delhi North Delhi, 110007 Delhi

Phone no: 9711885801

Email id: customercare@fin2research.com

Website: www.fin2research.com

For Research Query- researchdesk@fin2research.com